Immunologic and Prognostic Factors Associated with Overall Survival Employing a Poxviral-based PSA Vaccine in Metastatic Castrate-resistant Prostate Cancer

A concurrent multicenter, randomized Phase II trial employing a recombinant poxviral vaccine provided evidence of enhanced median overall survival (OS) (p=0.0061) in patients with metastatic castrate-resistant prostate cancer (mCRPC). The study reported here employed the identical vaccine in mCRPC t...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Gulley, James L., Arlen, Philip M., Madan, Ravi A., Tsang, Kwong-Yok, Pazdur, Mary P., Skarupa, Lisa, Jones, Jacquin L., Poole, Diane J., Higgins, Jack P., Hodge, James W., Cereda, Vittore, Vergati, Matteo, Steinberg, Seth M., Halabi, Susan, Jones, Elizabeth, Chen, Clara, Parnes, Howard, Wright, John J., Dahut, William L., Schlom, Jeffrey
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2009
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2832083/
https://ncbi.nlm.nih.gov/pubmed/19890632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-009-0782-8
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi